Aclaris

Analysts Expect Aclaris Therapeutics Inc (NASDAQ:ACRS) Will Post Quarterly Sales of $1.27 Million - Ticker Report | 4/6/2020

Brokerages expect Aclaris Therapeutics Inc (NASDAQ:ACRS) to report $1.27 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aclaris Therapeutics’ earnings, with the lowest sales estimate coming in at $1.13 million and the highest estimate coming in at $1.40 million. Aclaris Therapeutics posted sales of $5.04 million in the same quarter last year, which suggests a negative year over year growth …

Aclaris Therapeutics Inc (NASDAQ:ACRS) Expected to Post Earnings of -$0.29 Per Share - American Banking News | 4/4/2020

Equities research analysts expect that Aclaris Therapeutics Inc (NASDAQ:ACRS) will report ($0.29) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.29). Aclaris Therapeutics reported earnings of ($0.91) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 68.1%. The …

Follow Aclaris:    

Oxford Asset Management LLP Purchases New Shares in Aclaris Therapeutics Inc (NASDAQ:ACRS) - Dakota Financial News | 4/3/2020

Oxford Asset Management LLP Aclaris Therapeutics Inc (NASDAQ:ACRS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,599 shares of the biotechnology company’s stock, $52,000. Oxford Asset Management LLP owned approximately 0.07% of Aclaris Therapeutics at the end of the most recent quarter. Other large investors also recently bought and sold shares of the company. Man Group …

Renaissance Technologies LLC Raises Position in Aclaris Therapeutics Inc (NASDAQ:ACRS) | Daily Political | 4/2/2020

Renaissance Technologies LLC raised its holdings in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 41.3% during the 4th its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,782,297 shares of the biotechnology company’s stock after acquiring an additional 813,581 shares during the quarter. Renaissance Technologies LLC owned approximately 6.72% of Aclaris Therapeutics worth $5,259,000 as of its most recent filing with the Securities and …

Aclaris Therapeutics Secures $11 Million Term Loan Facility | 4/1/2020

Aclaris Therapeutics Secures $11 Million Term Loan Facility (Ref: GlobeNewswire) Print WAYNE, Pa., March 31, 2020 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and security agreement with Silicon Valley Bank (“SVB”) pursuant to which Aclaris has borrowed $11.0 million. “This financing allows us to strengthen our financial position by extending our cash runway and to continue …

Silicon Valley Bank Provides $11MM Term Loan to Aclaris Therapeutics | 4/1/2020

Aclaris Therapeutics Neal Walker Silicon Valley Bank Silicon Valley Bank Provides $11MM Term Loan to Aclaris Therapeutics Aclaris Therapeutics , a physician-led biopharmaceutical company, entered into a loan and security agreement with Silicon Valley Bank pursuant to which Aclaris has borrowed $11.0 million. “This financing allows us to strengthen our financial position by extending our cash runway and to continue to execute on our refocused business strategy as planned,” Dr …

Wayne biopharma firm borrows $11M to fund new business strategy | The Business Journals | 4/1/2020

Senior Reporter, Philadelphia Business Journal Apr 1, 2020, 11:07am EDT Updated Apr 1, 2020, 11:10am EDT Aclaris Therapeutics, a Wayne biopharmaceutical company that last year shifted its focus to immuno-inflammatory diseases, has borrowed $11 million under a loan and security agreement it entered into with Silicon Valley Bank . Aclaris CEO Dr. Neal Walker said the proceeds from the loan, in combination with the company’s existing cash and cash equivalents …

Short Interest in Aclaris Therapeutics Inc (NASDAQ:ACRS) Expands By 21.2% | Daily Political | 3/31/2020

… the short-interest ratio is presently 15.0 days. NASDAQ:ACRS opened at $1.02 on Tuesday. The stock’s fifty day moving average price is $1.16 and its two-hundred day moving average price is $1.50. Aclaris Therapeutics has a 52-week low of $0.70 and a 52-week high of $7.15. The company has a market cap of $46.93 million, a price-to-earnings ratio of -0.26 and a beta of …

Aclaris Therapeutics Inc (NASDAQ:ACRS) Short Interest Update | 3/29/2020

… trading volume, of 345,500 shares, the days-to-cover ratio is currently 15.0 days. Several institutional investors have recently modified their holdings of ACRS. Marshall Wace LLP purchased a new stake in shares of Aclaris Therapeutics in the first quarter worth approximately $103,000. Endurant Capital Management LP raised its stake in shares of Aclaris Therapeutics by 8.6% in the third quarter. Endurant Capital Management LP now owns 1,769,785 shares of …

Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Buy at ValuEngine - Ticker Report | 3/26/2020

… buy” rating in a note issued to investors on Tuesday, ValuEngine reports. Several other equities research analysts have also recently weighed in on the stock. SVB Leerink reaffirmed an “outperform” rating on shares of Aclaris Therapeutics in a research report on Thursday, January 2nd. cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 27th. One research analyst has rated …

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by ValuEngine to Buy - WKRB News | 3/26/2020

ValuEngine upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a buy rating in a report released on Tuesday morning, ValuEngine reports. ACRS has been the subject of a number of other reports. Zacks Investment Research cut shares of Aclaris Therapeutics from a hold rating to a sell note 27th. SVB Leerink reaffirmed an outperform rating on shares of Aclaris Therapeutics in a research note on Thursday …

Aclaris Therapeutics Inc (NASDAQ:ACRS) Receives Average Recommendation of “Hold” from Brokerages | 3/26/2020

Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have been given a consensus rating of “Hold” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the …

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by ValuEngine to Buy - WKRB News | 3/26/2020

ValuEngine upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a buy rating in a report released on Tuesday morning, ValuEngine reports. ACRS has been the subject of a number of other reports. Zacks Investment Research cut shares of Aclaris Therapeutics from a hold rating to a sell note 27th. SVB Leerink reaffirmed an outperform rating on shares of Aclaris Therapeutics in a research note on Thursday …

Investment Analysts’ Upgrades for March, 24th (ACRS, ALNPY, ALV, AZUL, BJRI, BKYI, BLD, CACC, CATO, CBMB) | 3/25/2020

Investment Analysts’ upgrades for Tuesday, March 24th: Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at ValuEngine from a hold rating to a buy rating. Get Aclaris Therapeutics Inc alerts: ANA HOLDINGS IN/S (OTCMKTS:ALNPY) was upgraded by analysts at ValuEngine from a sell rating to a hold rating. Autoliv (NYSE:ALV) was upgraded by analysts at ValuEngine from a sell rating to a hold rating. Azul (NYSE:AZUL …

2,087,312 Shares in Aclaris Therapeutics Inc (NASDAQ:ACRS) Acquired by EcoR1 Capital LLC | 3/25/2020

EcoR1 Capital LLC bought a new position in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,087,312 shares of the biotechnology company’s stock, valued at approximately $3,945,000. EcoR1 Capital LLC owned 5.04% of Aclaris Therapeutics at the end of the most recent reporting period. Other hedge funds and other institutional …

Aclaris Therapeutics (NASDAQ:ACRS) Trading 1.7% Higher - TheOlympiaReport | 3/24/2020

… shares were traded during trading. A decline of 75% from the average session volume of 540,007 shares. $0.90. ACRS has been the subject of several recent analyst reports. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, February 27th. ValuEngine cut shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on …

The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company | 3/20/2020

… IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX …

Aclaris Therapeutics (NASDAQ:ACRS) Cut to Hold at ValuEngine - Transcript Daily | 3/19/2020

ValuEngine downgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a buy rating to a hold rating in a research note published on Sunday morning, ValuEngine reports. ACRS has been the topic of a number of other research reports. SVB Leerink reaffirmed an outperform rating on shares of Aclaris Therapeutics in a research note on Thursday, January 2nd. Zacks Investment Research downgraded Aclaris Therapeutics from a hold rating to a sell …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Daily Biotech Pulse: Pfizer’s Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic’s COVID-19 Connection | Benzinga | 3/19/2020

… NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna …

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by ValuEngine | 3/18/2020

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded by ValuEngine Posted by John Perry on Mar 18th, 2020 Tweet ValuEngine lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from a buy rating to a hold rating in a research report sent to investors on Sunday morning, ValuEngine reports. Several other analysts have also issued reports on the stock. SVB Leerink reiterated an outperform rating on shares of Aclaris Therapeutics in a research report on …

Analysts’ Updated EPS Estimates for March, 15th (ACRS, ADBE, AQST, CPCAY, KMI, LUNMF, LXRX, PFLT, SAR, SLAB) | 3/16/2020

Analysts’ updated eps estimates for Sunday, March 15th: Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by analysts at ValuEngine from a buy rating to a hold rating. Get Aclaris Therapeutics Inc alerts: Adobe (NASDAQ:ADBE) had its buy rating reiterated by analysts at Barclays PLC. They currently have a $333.00 target price on the stock. Aquestive Therapeutics (NASDAQ:AQST) had its buy rating reiterated by analysts at Wedbush. Wedbush currently has …

Broadfin Capital LLC Purchases 268,039 Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) | 3/16/2020

Broadfin Capital LLC increased its position in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 16.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,888,039 shares of the biotechnology company’s stock after purchasing an additional 268,039 shares during the quarter. Broadfin Capital LLC owned approximately 4.56% of Aclaris Therapeutics worth $3,568,000 at the end of the most …

Preclinical Stage Partnering Deals in Pharma & Biotech, 2014-2020 - Access to 1,400+ Deal Records; Leading Deals by Value, Most Active Dealmakers | PR Newswire | 3/16/2020

… for Science Technology and Research AB-Biotics AB Biosciences Abbott Laboratories Abbvie AbClon Ab E Discovery Abeona Therapeutics Abide Therapeutics ABL Bio Abpro Abzena Accelovance AccuGenomics Acetylon Pharmaceuticals Achaogen Achieve Life Science AC Immune Aclaris Therapeutics ACT Biotech Acticor Biotech Actinium Pharmaceuticals Acucela AcuraStem Acurx Pharmaceuticals AdAlta Adaptimmune Adapt Pharma ADC Therapeutics Addex Therapeutics Adimab Aduro BioTech Advaita Advanced Accelerator Applications Advanced BioScience Laboratories Advaxis Aerie Pharmaceuticals Aevi Genomic Medicine …

Aclaris Therapeutics (NASDAQ:ACRS) Rating Lowered to Hold at ValuEngine - Ticker Report | 3/15/2020

Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday, ValuEngine reports. A number of other research analysts have also recently commented on ACRS. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 27th. SVB Leerink restated an “outperform” rating …

Aclaris Therapeutics Inc (NASDAQ:ACRS) Holdings Raised by MFN Partners Management LP | Daily Political | 3/15/2020

MFN Partners Management LP raised its holdings in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 166.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,000,000 shares of the biotechnology company’s stock after purchasing an additional 2,500,000 shares during the quarter. Aclaris Therapeutics accounts for approximately 1.6% of MFN Partners Management LP’s investment portfolio, making the stock its 9th …

Adverse Drug Reactions

Rigel Announces Third Quarter 2019 Financial Results | PR Newswire | 11/5/2019

… 9.1 million for the three months ended September 30, 2019 , of which $4.0 million related to a development milestone from Aclaris Therapeutics, Inc., $3.8 million related to a commercial launch milestone from Impact Biomedicines, Inc … the BCRP and P-gp substrate drug. Adverse Reactions Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, which occurred in 1% of TAVALISSE patients. In …

Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call | PR Newswire | 10/23/2019

… drugs (eg, digoxin), which may require a dose reduction of the BCRP and P-gp substrate drug. Adverse Reactions Serious adverse drug reactions in the ITP double-blind studies were febrile neutropenia, diarrhea, pneumonia, and … product candidates in development with partners BerGenBio ASA, Daiichi Sankyo, Aclaris Therapeutics, and AstraZeneca. 1 The product candidate is investigational and has not been established safe or effective by the U.S. Food and Drug Administration …

Biotech

Biotech stocks win October, rallying 8% | CNBC | 10/31/2019

A Biogen Idec lab technician Suzanne Kreiter The Boston Globe Getty Images Biotechnology stocks are emerging as the standout performers in October. The Biotech ETF (IBB) is up 8% in October, while the S&P … back to its initial public offering in May 2016. Achillion , Aclaris and Ra Pharmaceuticals are other standout performers this month. It is important to note the Biotech ETF is up about 11% this year, lagging …

The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug | 10/25/2019

Here’s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat … Assessing Mirati’s Oncology Franchise With An Eye On Multiple Readouts Aclaris Aces a Late-stage Study of Treatment For Common Warts Aclaris Therapeutics Inc (NASDAQ: ACRS ) announced positive results from a second Phase 3 study …

Food and Drug Administration

Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call | PR Newswire | 10/23/2019

Aclaris Therapeutics, and AstraZeneca. 1 The product candidate is investigational and has not been established safe or effective by the U.S. Food and Drug Administration (FDA) or any regulatory authority. Forward Looking Statements This release contains forward-looking statements relating to, among other things, the continued growth of commercial sales of TAVALISSE in the U.S.; Rigel’s third quarter net product sales results; the potential expansion of fostamatinib into other countries …

Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1% Nasdaq:ACRS | Globe Newswire | 10/9/2019

WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today that the company, together with Allergan, Inc., has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Taro Pharmaceuticals, Inc. (“Taro”), related to an Abbreviated New Drug Application (“ANDA”) that Taro filed with the U.S. Food and Drug …

ACA

Top Ranked Momentum Stocks to Buy for October 3rd - October 3, 2019 - Zacks.com | 10/3/2019

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 3rd: Aclaris Therapeutics, Inc. ( ACRS - Free Report ) : This biopharmaceutical company has a Zacks Rank 2 (Buy) and witnessed … Ally Financial Inc. price Ally Financial Inc. Quote: Arcosa, Inc. ( ACA - Free Report ) : This provider of infrastructure-related products and solutions has a Zacks Rank 2 (Buy) and witnessed the Zacks Consensus Estimate for its …

Topical Drug Delivery Market Worth $123.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™ | PR Newswire | 8/9/2019

… This is primarily due to the high incidence of skin disorder across the globe. For instance, According to the American Academy of Dermatology (AAD), skin cancer is one of the most common cancers in the … management of pain in the US. Similarly, in December 2017 , Aclaris Therapeutics Inc. (US), launched ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the treatment of raised seborrheic keratosis in the US market. Get …

Big Pharma

Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors | Benzinga | 7/4/2019

WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of … developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in …

Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors - Stock Market News on Stocks News Feed | 7/4/2019

WAYNE, Pa., Aclaris Therapeutics, Inc. ( NASDAQ : ACRS ), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019 … developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in …

Allergan

Aclaris’ MK2 Inhibitor Shows Encouraging Data in Phase I | Zacks | 1/14/2020

Aclaris’ MK2 Inhibitor Shows Encouraging Data in Phase I Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More … inflammatory pipeline. Notably, Aclaris acquired the rights to Rhofade from Allergan ( AGN - Free Report ) in 2018. The company is currently developing its pipeline candidate, A-101 45% topical solution for the treatment of common warts …

Grifols

Rigel Pharmaceuticals Provides Business Update | PR Newswire | 1/13/2020

… beginning in the second half of the year, and importantly, we will receive a $20 million milestone from our partner, Grifols, S.A.,” stated Mr. Rodriguez, Rigel’s president and CEO. “Enrollment of our Phase 3 clinical … in October 2019 of the license and collaboration agreement with Aclaris dated August 27, 2015 , as well as deferred revenue from its collaboration with Grifols related to the performance of certain research and development services …

Sorrento Therapeutics

33 Stocks Moving in Friday’s Pre-Market Session | 1/10/2020

Gainers Sorrento Therapeutics Inc (NASDAQ: SRNE ) rose 64.8% to $5.62 in pre-market trading after the company received non-binding acquisition proposal at $7 per share. Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) shares rose 23.7% to $2.30 in pre-market trading after the company announced positive results from ATI-450-PKPD-101. Moderna, Inc. (NASDAQ: MRNA ) rose 19.6% to $22.00 in pre-market trading after the company announced positive data from …

Merck

Global Human Papillomavirus Infection Drug Market Professional Survey Report 2019 | 11/22/2019

… This report focuses on Human Papillomavirus Infection Drug Human Papillomavirus Infection Drug Human Papillomavirus Infection Drug Human Papillomavirus Infection Drug Merck 1 Industry Overview of Human Papillomavirus Infection Drug 1.1 Definition of Human Papillomavirus Infection … Gross Margin (2014-2019) 8.1.4 Main Business and Markets Served 8.2 Aclaris Therapeutics 8.2.1 Aclaris Therapeutics Human Papillomavirus Infection Drug Production Sites and Area Served 8.2.2 Aclaris Therapeutics Product Introduction, Application and Specification 8.2.3 Aclaris Therapeutics …

Biogen

Global Human Papillomavirus Infection Drug Market Professional Survey Report 2019 | 11/22/2019

… Human Papillomavirus Infection Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019) 8.1.4 Main Business and Markets Served 8.2 Aclaris Therapeutics 8.2.1 Aclaris Therapeutics Human Papillomavirus Infection Drug Production Sites and Area Served 8.2.2 … Gross Margin (2014-2019) 8.3.4 Main Business and Markets Served 8.4 Biogen Idec 8.4.1 Biogen Idec Human Papillomavirus Infection Drug Production Sites and Area Served 8.4.2 Biogen Idec Product Introduction, Application and Specification 8.4.3 Biogen Idec …

Celgene

Rigel Announces Third Quarter 2019 Financial Results | PR Newswire | 11/5/2019

Aclaris Therapeutics, Inc., $3.8 million related to a commercial launch milestone from Impact Biomedicines, Inc., which was subsequently acquired by Celgene Corp., and $1.3 million from its collaboration agreements with Grifols, S.A. and Kissei Pharmaceutical Co., Ltd. related to performance of certain research and development services. There were no contract revenues from collaborations during the three months ended September 30, 2018 . Rigel reported total costs and expenses of $32.9 million …

Celgene Corp

Rigel Announces Third Quarter 2019 Financial Results | PR Newswire | 11/5/2019

Aclaris Therapeutics, Inc., $3.8 million related to a commercial launch milestone from Impact Biomedicines, Inc., which was subsequently acquired by Celgene Corp., and $1.3 million from its collaboration agreements with Grifols, S.A. and Kissei Pharmaceutical Co., Ltd. related to performance of certain research and development services. There were no contract revenues from collaborations during the three months ended September 30, 2018 . Rigel reported total costs and expenses of $32.9 million …

Genentech

Rigel Announces Third Quarter 2019 Financial Results | PR Newswire | 11/5/2019

… 9.1 million for the three months ended September 30, 2019 , of which $4.0 million related to a development milestone from Aclaris Therapeutics, Inc., $3.8 million related to a commercial launch milestone from Impact Biomedicines, Inc … of clinical and drug development experience with companies such as Genentech, Inc., Biomarin Pharmaceuticals, Inc., and Aridis Pharmaceuticals, Inc., as well as an extensive academic history. About ITP In patients with ITP (immune thrombocytopenia), the …

Incyte

Vitiligo: First-ever RCT is smashing success | 10/29/2019

… Incyte, the study sponsor. He has similar financial relationships with Pfizer, Aclaris Therapeutics, and the Immune Tolerance Network. Next Article …

Edwards Lifesciences

The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug | 10/25/2019

… Biotech stocks hitting 52-week highs on Oct. 24) AstraZeneca plc (NYSE: AZN ) (reacted to a beat-and-raise quarter) Edwards Lifesciences Corp (NYSE: EW )( reported better-than-expected third-quarter results) Frequency Therapeutics Inc … Assessing Mirati’s Oncology Franchise With An Eye On Multiple Readouts Aclaris Aces a Late-stage Study of Treatment For Common Warts Aclaris Therapeutics Inc (NASDAQ: ACRS ) announced positive results from a second Phase 3 study …

Alexion Pharmaceuticals

Stealth BioTherapeutics Does The Deal With Alexion, And Other Headlines: The Good, Bad And Ugly Of Biopharma - Stealth BioTherapeutics Corp (NASDAQ:MITO) | Seeking Alpha | 10/13/2019

On the good news front in today’s series, Stealth BioTherapeutics ( MITO ) and Alexion Pharmaceuticals ( ALXN ) have agreed to co-develop and commercialize elamipretide for mitochondrial diseases. Elamipretide, an inner mitochondrial membrane-targeting therapeutic, is Stealth … TARO ) has been hit with a patent infringement lawsuit by Aclaris Therapeutics ( ACRS ) together with Allergan plc ( AGN ). Taro had filed an ANDA with the U.S. FDA, seeking approval to manufacture and market a generic …

AbbVie

Pipeline Review on Hidradenitis Suppurativa Pipeline Review - H2 2019 | PR Newswire | 10/9/2019

AbbVie Inc Aclaris Therapeutics Inc Alvotech ehf AstraZeneca Plc Celgene Corp ChemoCentryx Inc CSL Ltd Foamix Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd Immunwork Inc Incyte Corp InflaRx NV Innovation Pharmaceuticals Inc InSight Biopharmaceuticals Ltd Johnson & Johnson Novartis AG UCB SA XBiotech Inc Hidradenitis Suppurativa - Drug Profiles ABBV-3373 - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab …

Novartis

Pipeline Review on Hidradenitis Suppurativa Pipeline Review - H2 2019 | PR Newswire | 10/9/2019

Aclaris Therapeutics Inc Alvotech ehf AstraZeneca Plc Celgene Corp ChemoCentryx Inc CSL Ltd Foamix Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd Immunwork Inc Incyte Corp InflaRx NV Innovation Pharmaceuticals Inc InSight Biopharmaceuticals Ltd Johnson & Johnson Novartis AG UCB SA XBiotech Inc Hidradenitis Suppurativa - Drug Profiles ABBV-3373 - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress adalimumab biosimilar - Drug …

Zimmer Biomet

Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/6/2019

NEW YORK, Oct. 06, Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (NASDAQ: PSMT), Pyxus International, Inc. (NYSE: PYX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. PriceSmart, Inc. (NASDAQ: PSMT) Bragar Eagel and Squire is investigating certain officers and directors of PriceSmart …

Sarepta Therapeutics

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC | Globe Newswire | 9/27/2019

… its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Class Period: September 6, 2017 - August 19, 2019 Deadline: October … statements were materially false and misleading at all relevant times. Aclaris Therapeutics, Inc. (NASDAQ: ACRS) Class Period: May 8, 2018 - June 20, 2019 Deadline: October 30, 2019 For more info: www.bgandg.com/acrs The complaint alleges …

Oasmia Pharmaceutical

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investors to Contact the Firm | Globe Newswire | 9/11/2019

September 10, 2019 19:30 ET Source: Bragar Eagel & Squire NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of National General Holdings Corp. (NASDAQ: NGHC), Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), and Aclaris Therapeutics, Inc. (NASDAQ: ACRS). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff …

Evolent Health

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Oasmia Pharmaceutical, Aclaris Therapeutics, Evolent Health, and International Flavors & Fragrances and Encourages Investors to Contact the Firm | Globe Newswire | 8/27/2019

August 27, 2019 08:00 ET Source: Bragar Eagel & Squire NEW YORK, Aug. 27, Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), Evolent Health, Inc. (NYSE: EVH), and International Flavors & Fragrances, Inc. (NYSE: IFF). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information …

Curaleaf

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm | Globe Newswire | 8/19/2019

August 18, 2019 19:30 ET Source: Bragar Eagel & Squire NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), and Curaleaf Holdings, Inc. (Other OTC: CURLF). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff …

GlaxoSmithKline

Topical Drug Delivery Market Worth $123.2 Billion by 2024 - Exclusive Report by MarketsandMarkets™ | PR Newswire | 8/9/2019

Aclaris Therapeutics Inc. (US), launched ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the treatment of raised seborrheic keratosis in the US market. Get 10% Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=124871717 Prominent players in the Topical Drug Delivery Market are Novartis AG ( Switzerland ), Johnson & Johnson (US), Bausch Health Companies ( Canada ), Nestle SA ( Switzerland ), GlaxoSmithKline (UK), Mylan (US), Merck & Co (US), Bayer AG ( Germany ), Hisamitsu Pharmaceutical ( Japan …

Omnicell

Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation | PR Newswire | 7/27/2019

… the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected] . Aclaris Therapeutics, Inc. (ACRS) Lifshitz & Miller announces investigation into possible securities laws violations in connection … telephone at (516)493-9780 or e-mail at [email protected] . Omnicell, Inc. (OMCL) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations of OMCL engaging in improper accounting revenue practices. If …

Acer Therapeutics

Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation | PR Newswire | 7/27/2019

NEW YORK Acer Therapeutics Inc. (ACER) Lifshitz & Miller announces investigation into possible securities laws violations in connection with a CRL for EDSIVO. If you are an ACER investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected] . Aclaris Therapeutics, Inc. (ACRS) Lifshitz & Miller announces investigation into possible securities laws …

Zebra Technologies

Leerink Swann Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Market Perform | 7/20/2019

Leerink Swann Downgrades Aclaris Therapeutics (NASDAQ:ACRS) to Market Perform Posted by Cindy Kellogue on Jul 19th, 2019 Leerink Swann downgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from an outperform rating to a market perform … 13.00 target price on the stock. BidaskClub lowered shares of Zebra Technologies from a buy rating to a hold rating in a research note on Wednesday, May 8th. Cantor Fitzgerald restated an overweight rating and …

Bausch Health

Amneal and Mylan weigh on generic players - Aclaris Therapeutics, Inc. (NASDAQ:ACRS) | Seeking Alpha | 7/10/2019

Generic drug makers are mostly in the red in apparent sympathy with drops in Amneal Pharmaceuticals ( -33% on restructuring and softer guidance) and Mylan ( -5% on continued EpiPen shortage ). Selected tickers: Aclaris Therapeutics ( ACRS -4.7% ), Akorn ( AKRX -2.8% ), Amphastar Pharmaceuticals ( AMPH ), ANI Pharmaceuticals ( ANIP -2% ), Bausch Health Companies ( BHC -0.8% ), Teva Pharmaceutical Industries ( TEVA -3.6% ), Coherus BioSciences ( CHRS -1.8% ), Collegium Pharmaceutical ( COLL -0.9% ), Eagle Pharmaceuticals ( EGRX -1.8% ), Endo International ( ENDP …

Bausch Health Companies

Amneal and Mylan weigh on generic players - Aclaris Therapeutics, Inc. (NASDAQ:ACRS) | Seeking Alpha | 7/10/2019

Generic drug makers are mostly in the red in apparent sympathy with drops in Amneal Pharmaceuticals ( -33% on restructuring and softer guidance) and Mylan ( -5% on continued EpiPen shortage ). Selected tickers: Aclaris Therapeutics ( ACRS -4.7% ), Akorn ( AKRX -2.8% ), Amphastar Pharmaceuticals ( AMPH ), ANI Pharmaceuticals ( ANIP -2% ), Bausch Health Companies ( BHC -0.8% ), Teva Pharmaceutical Industries ( TEVA -3.6% ), Coherus BioSciences ( CHRS -1.8% ), Collegium Pharmaceutical ( COLL -0.9% ), Eagle Pharmaceuticals ( EGRX -1.8% ), Endo International ( ENDP …

GSK

Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors | Benzinga | 7/4/2019

Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of directors, effective July 2, 2019. Dr. Gowen founded Trevena, Inc. and served as its President and Chief Executive Officer from 2007 until October 2018. Prior to this, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of …

Zacks Equity Research

Aclaris’ MK2 Inhibitor Shows Encouraging Data in Phase I | Zacks | 1/14/2020

Aclaris’ MK2 Inhibitor Shows Encouraging Data in Phase I Zacks Equity Research You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Aclaris Therapeutics, Inc. ( ACRS - Free Report ) announced positive data from the phase I ATI-450-PKPD-101 study on it investigational MK2 inhibitor, ATI-450, currently being developed for addressing immuno-inflammatory …

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release | Zacks | 10/29/2019

You follow Tale of the Tape - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article Wall Street expects a year-over-year increase in earnings on higher revenues when Aclaris Therapeutics ( ACRS - Free Report ) reports results for the quarter ended September 2019. While this widely-known consensus outlook is important in gauging the company’s earnings picture, a …

Daiichi Sankyo

Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results | PR Newswire | 10/29/2019

Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo. Please see www.TAVALISSE.com for the full Prescribing Information. Contact: David Burke Phone: 650.624.1232 Email: [email protected] SOURCE Rigel Pharmaceuticals, Inc. Related Links https://www.rigel.com …

Rigel to Host Investor and Analyst Call on October 23, 2019 | PR Newswire | 10/16/2019

… Daiichi Sankyo, Aclaris Therapeutics, and AstraZeneca. Please see www.TAVALISSE.com for full Prescribing Information. Contact: David Burke Phone: 650.624.1232 Email: [email protected] SOURCE Rigel Pharmaceuticals, Inc. Related Links http://www.rigel.com …

William Blair

Aclaris Therapeutics (NASDAQ:ACRS) Rating Reiterated by William Blair | 10/15/2019

Aclaris Therapeutics (NASDAQ:ACRS) ‘s stock had its “buy” rating restated by equities researchers at William Blair in a report released on Friday, TipRanks reports.A number of other equities analysts have also recently weighed in on the stock. Svb Leerink cut shares of Aclaris Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday, June 27th. raised shares of Aclaris Therapeutics from a “hold …

Aclaris Therapeutics’ (ACRS) “Buy” Rating Reiterated at William Blair | 10/15/2019

William Blair reissued their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note released on Friday, TipRanks reports. A number of other research analysts also recently issued reports on ACRS. Leerink Swann downgraded Aclaris Therapeutics from an outperform rating to a market perform rating in a report on Thursday, June 27th. Svb Leerink downgraded Aclaris Therapeutics from an outperform rating to a market perform rating in …

JMP Securities

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by JMP Securities | 9/10/2019

Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by JMP Securities Posted by David Glaser on Sep 10th, 2019 // Comments off JMP Securities lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from an outperform rating to a market perform rating in a research report report published on Friday, BenzingaRatingsTable reports. A number of other brokerages also recently commented on ACRS. Leerink Swann downgraded Aclaris Therapeutics from an outperform rating to a market …

JMP Securities Lowers Aclaris Therapeutics (NASDAQ:ACRS) to Market Perform - Ticker Report | 9/9/2019

JMP Securities lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from an outperform rating to a market perform rating in a report issued on Friday morning, BenzingaRatingsTable reports. A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Aclaris Therapeutics from a buy rating to a hold report on Thursday. Svb Leerink downgraded Aclaris Therapeutics from an outperform rating to a market perform …

SR One

Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors Nasdaq:ACRS | Globe Newswire | 7/3/2019

July 03, 2019 16:01 ET Source: Aclaris Therapeutics, Inc. WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced … pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in, and served on the board of directors of, numerous companies. Until …

Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors | Markets Insider | Business Insider | 7/3/2019

WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) – Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced the appointment of Maxine Gowen to its board of … pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in, and served on the board of directors of, numerous companies. Until …

SVB Leerink

U.S. STOCKS ON THE MOVE-Conagra, Walgreens, Zogenix, Aclaris Therapeutics - Nasdaq.com | 6/27/2019

… 311.7% Cemtrex Inc , up 137.2% Zogenix Inc , up 22.5% The top three Nasdaq percentage losers: XpresSpa Group Inc , down 53.7% Aclaris Therapeutics Inc , down 40.3% Zynex Inc , down 23.9% Boeing Co : down 2.6% Down on … Magellan Health Inc : up 2.9% Seems destined for private equity - SVB Leerink KB Home : up 7.7% Shares rise as strong order growth helps Q2 profit beat Seelos Therapeutics Inc : up 3.6% Soars on new license …

U.S. STOCKS ON THE MOVE-Conagra, Adaptive Biotechnologies, Aclaris Therapeutics, Peak Resorts - Nasdaq.com | 6/27/2019

… ASV Holdings Inc , up 316% Cemtrex Inc , up 121.3% Adaptive Biotechnologies Corp , up 97% The top three Nasdaq percentage losers: Aclaris Therapeutics Inc , down 46.3% Riot Blockchain , down 21.6% Marathon Patent Group Inc , down 19.9 … Magellan Health Inc : up 1.5% Seems destined for private equity - SVB Leerink KB Home : up 6.8% Shares rise as strong order growth helps Q2 profit beat Seelos Therapeutics Inc : up 3.6% Soars on new license …

Aisling Capital

Aclaris Therapeutics Inc (ACRS) Stake Lifted by Geode Capital Management LLC | 4/29/2019

Geode Capital Management LLC lifted its position in Aclaris Therapeutics Inc (NASDAQ:ACRS) by 38.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 380,007 shares of the … after purchasing an additional 1,103,423 shares during the last quarter. Aisling Capital Management LP bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth approximately $4,689,000. Man Group plc lifted its …

Aclaris Therapeutics Inc (ACRS) Shares Sold by Bank of New York Mellon Corp | 4/26/2019

Aclaris Therapeutics Inc (ACRS) Shares Sold by Bank of New York Mellon Corp Posted by Daniel Jordon on Apr 26th, 2019 // Comments off Bank of New York Mellon Corp lowered its holdings in shares of … after buying an additional 1,103,423 shares during the last quarter. Aisling Capital Management LP purchased a new position in Aclaris Therapeutics during the 4th quarter worth $4,689,000. Prudential Financial Inc. purchased a new position in …

Epidarex Capital

Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences | PR Newswire | 12/7/2017

BETHESDA, Md. , Dec. 7, 2017 /PRNewswire/ – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today announced that its portfolio company, Harpoon Medical, Inc. (“Harpoon”), a pioneer in beating-heart repair for degenerative … follows the successful sale of Confluence Life Sciences, Inc., to Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) in August for a total deal value of up to $100 million in up-front and milestone payments, and the …

Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences | PR Newswire | 12/7/2017

Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences Acquisition Marks Further Success for the Epidarex Portfolio News provided by 06:00 ET Share this article BETHESDA, Md. , Dec. 7, 2017 /PRNewswire/ – Epidarex Capital (“Epidarex … follows the successful sale of Confluence Life Sciences, Inc., to Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) in August for a total deal value of up to $100 million in up-front and milestone payments, and the …

Tim Lugo

Aclaris Therapeutics (ACRS) Receives a Buy from William Blair | 1/10/2020

Aclaris Therapeutics (ACRS) Receives a Buy from William Blair Christine Brown - January 10, 2020, 1:39 PM EDT SHARE ON: In a report released today, Tim Lugo from William Blair maintained a Buy rating on Aclaris Therapeutics ( ACRS ). The company’s shares closed last Monday at $2.17. According to TipRanks.com , Lugo is a 5-star analyst with an average return of 14.0% and a 48.9% success rate. Lugo covers the Healthcare sector …

Leo Kandinov

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS) | Business Wire | 11/27/2019

SAN DIEGO & WAYNE, Pa.- Shareholder rights law firm Robbins LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a derivative complaint against the company’s officers and directors for breaches of fiduciary duties … 2019 closing price of $5.11. Contact us to learn more: Leo Kandinov (800) 350-6003 [email protected] Shareholder Information Form Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and …

David Gordon

Aclaris Therapeutics to Present at Upcoming Investor Conferences | Globe Newswire | 11/12/2019

November 12, 2019 16:01 ET Source: Aclaris Therapeutics, Inc. WAYNE, Pa., Nov. 12, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced that management will present at … Changelian, Ph.D. - VP, Biology Jon Jacobsen, Ph.D. - VP, Chemistry Dr. David Gordon - Chief Medical Officer Dr. Walker will also present a company overview at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4 …

Bragar Eagel

Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm | Globe Newswire | 10/6/2019

October 06, 2019 10:00 ET Source: Bragar Eagel & Squire NEW YORK, Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (NASDAQ: PSMT), Pyxus International, Inc. (NYSE: PYX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Zimmer Biomet Holdings, Inc. (NYSE: ZBH) on behalf of long-term stockholders. More information about each potential case can be found at the link provided. PriceSmart, Inc. (NASDAQ: PSMT) Bragar Eagel and Squire is …

Brandon Walker

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm | Business Wire | 9/28/2019

… in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (NYSE: ACRS) securities between May 8, 2018 and June 29, 2019 (the … rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form. There is no …

Melissa Fortunato

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Aclaris Therapeutics, Inc. (NYSE: ACRS) and Encourages Aclaris Investors to Contact the Firm | Business Wire | 9/28/2019

… in the United States District Court for the Southern District of New York on behalf of all investors that purchased Aclaris Therapeutics, Inc. (NYSE: ACRS) securities between May 8, 2018 and June 29, 2019 (the … with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation …

Peretz Bronstein

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC | Globe Newswire | 9/27/2019

… publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC … statements were materially false and misleading at all relevant times. Aclaris Therapeutics, Inc. (NASDAQ: ACRS) Class Period: May 8, 2018 - June 20, 2019 Deadline: October 30, 2019 For more info: www.bgandg.com/acrs The complaint alleges …

Yael Hurwitz

Sarepta Therapeutics, Inc. (SRPT), Aclaris Therapeutics, Inc. (ACRS) & Canada Goose Holdings Inc. (GOOS) - Class Action Update - Bronstein, Gewirtz & Grossman, LLC | Globe Newswire | 9/27/2019

… of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 . If you suffered a loss, you … statements were materially false and misleading at all relevant times. Aclaris Therapeutics, Inc. (NASDAQ: ACRS) Class Period: May 8, 2018 - June 20, 2019 Deadline: October 30, 2019 For more info: www.bgandg.com/acrs The complaint alleges …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aclaris Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - ACRS | PR Newswire | 9/26/2019

NEW YORK , Sept. Pomerantz LLP announces that a class action lawsuit has been filed against Aclaris Therapeutics Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) and certain of its officers. The class action, filed in United … can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Globe Newswire | 9/25/2019

Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) investors who purchased securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy

Richard Gonnello

ACLARIS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aclaris Therapeutics, Inc. To Contact The Firm | The Wapakoneta Daily News | 9/25/2019

… New York, New York - ( NewMediaWire ) - September 25, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) ( NASDAQ: ACRS ) of the September 30, 2019 deadline … obligation to you. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected] CONTACT: FARUQI & FARUQI, LLP 685 Third Avenue …

Phillip Kim

ACRS LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action - ACRS | PR Newswire | 9/23/2019

Aclaris Therapeutics, Inc. from May 8, 2018 through June 20 , 2019, inclusive (the “Class Period”) of the important September 30, 2019 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for Aclaris investors under the federal securities laws. To join the Aclaris class action, go to http://www.rosenlegal.com/cases-register-1637.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or …

Brian Schall

7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Globe Newswire | 9/23/2019

… ANGELES, The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS ) for violations of §§10(b) and … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

Howard G. Smith

Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aclaris Therapeutics, Inc. | Globe Newswire | 9/20/2019

September 20, 2019 11:00 ET Source: Law Offices of Howard G. Smith BENSALEM, Pa., Law Offices of Howard G. Smith reminds investors of the upcoming September 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS ) securities between May 8, 2018 and June 20, 2019 , inclusive (the “Class Period”). Investors suffering …

Laurence Rosen

GLOBALLY RECOGNIZED ROSEN LAW FIRM Reminds Aclaris Therapeutics, Inc. Investors of Important September 30th Deadline in Securities Class Action – ACRS | Business Wire | 9/13/2019

… BUSINESS WIRE)–Sep 12, 2019– Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) from May 8, 2018 through June 20, 2019, inclusive (the … version on businesswire.com : https://www.businesswire.com/news/home/20190912005915/en/ CONTACT: Laurence Rosen, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34thFloor …

Julian Aleksov

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Carbonite and Encourages Investors to Contact the Firm | Globe Newswire | 9/4/2019

… class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE: MNK), Oasmia Pharmaceutical AB (NASDAQ: OASM), Aclaris Therapeutics, Inc. (NYSE: ACRS), and Carbonite, Inc. (NASDAQ: CARB). Stockholders have until the deadlines … stated it had ended its relationship with former executive chairmen Julian Aleksov because of the transactions mentioned in the Company’s June 28, 2019 press release. On this news, shares of Oasmia fell $0.34, or over …

Abraham L. Pomerantz

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS | Markets Insider | Business Insider | 8/24/2019

NEW YORK , Aug. 24, 2019 /PRNewswire/ – Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS). Such investors are advised to contact Robert S. Willoughby at … corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than …

Mark Senak

FDA promo police spank Aclaris for misleading info in Eskata video | FiercePharma | 7/8/2019

Aclaris Therapeutics is the latest pharma on the hot seat with the FDA’s promotion enforcers. In this case, the Office of Prescription Drug Promotion is targeting a DTC video it deems misleading. OPDP issued its … imaging drug Eye on FDA blogger and public relations professional Mark Senak wrote about the latest letter, noting that in the context of fewer OPDP letters this year, this missive might mean the agency is …

Louise Chen

Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q1 2019 Results - Earnings Call Transcript | Seeking Alpha | 5/9/2019

Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) Q1 2019 Earnings Conference Call May 8, 2019 5:00 PM ET Company Participants Kamil Ali-Jackson - Chief Legal Officer Neal Walker - President & Chief Executive Officer Stuart Shanler - Chief Scientific Officer Frank Ruffo - Chief Financial Officer David Gordon - Chief Medical Officer Jeff Wayne - Interim Head of Commercial. Conference Call Participants Louise Chen - Cantor Liav Abraham - Citi Dylan Dupuis - SVB Leerink. Tim Lugo - William Blair Operator Good …

Kyp Sirinakis

Epidarex Capital Portfolio Company Harpoon Medical Acquired By Edwards Lifesciences | PR Newswire | 12/7/2017

Kyp Sirinakis , Managing Partner, Epidarex. “Harpoon is a good example of how Epidarex identifies and funds the most promising early-stage technologies in under-ventured markets. Harpoon exemplifies the Epidarex strategy of successfully building highly innovative companies that are addressing large, unmet medical needs with solutions that provide significant benefits to patients.” The Harpoon acquisition follows the successful sale of Confluence Life Sciences, Inc., to Aclaris Therapeutics, Inc. (NASDAQ: ACRS …